Efficacy of methotrexate in Crohn’s disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine
Open accessThe DOI matches its Crossref record.
Abstract
Summary: Background Despite the wide use of azathioprine/mercaptopurine (AZA/MP) therapy in the management of both Crohn’s disease (CD) and ulcerative colitis (UC), approximately 20% of patients cannot tolerate the drugs and 30% do not respond. Aim To examine the efficacy and safety profile of methotrexate (MTX) in patients with CD or UC who are either intolerant or non‐responsive to AZA/MP. Methods A total of 131 patients with IBD treated with MTX were identified. Retrospective data were obtained by case note review. Clinical response (defined as steroid withdrawal, normalization of previously raised CRP or physician’s clinical assessment of improvement) was assessed at 6 months. Results Clinical response in Crohn’s disease occurred in 18 of 29 patients (62%) refractory to AZA/MP and 42 of 70 patients (60%) intolerant to AZA/MP, with no difference between the groups (P = 1.0). In UC, clinical response was seen in 7 of 9 (78%) patients refractory to AZA/MP and 15 of 23 (65%) intolerant to thiopurines. MTX was well tolerated in a majority of individuals. Conclusions Methotrexate appears effective in both CD and UC patients who fail to respond to or are intolerant to AZA/MP therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548
Self-citationGuidelines for the management of inflammatory bowel disease in adults
Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., et al. (2011) · Gut · doi:10.1136/gut.2010.224154 · Cited by 1,419
Self-citationHarbord, M., Eliakim, R., Bettenworth, D., Karmiris, K., Katsanos, K., Kopylov, U., Kucharzik, T., Molnár, T., Raine, T., Sebastian, S., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx009 · Cited by 1,180
Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease
Navaneethan, U., & Shen, B. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21219 · Cited by 201
“In a study of 131 IBD patients treated with methotrexate, 4 of 8 patients who developed abnormal LFTs had to stop the agent.(193) While evidence from methotrexate use in other conditions including psoriasis and rheumatoid arthritis suggests that LFTs need to be monitored in”
Background
Metadata
- Authors
- WAHED, M., LOUIS‐AUGUSTE, J. R., BAXTER, L. M., LIMDI, J. K., MCCARTNEY, S. A., LINDSAY, J. O., & BLOOM, S. L.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2009-08-18
- Volume
- 30
- Issue
- 6
- Pages
- 614-620
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W1992761307
- Cited by
- 98
- References
- 0
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of methotrexate in Crohn’s disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine. https://app.cochat.ai/papers/10.1111/j.1365-2036.2009.04073.x
- The paper
- WAHED, M., LOUIS‐AUGUSTE, J. R., BAXTER, L. M., LIMDI, J. K., MCCARTNEY, S. A., LINDSAY, J. O., & BLOOM, S. L. (2009). Efficacy of methotrexate in Crohn’s disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2009.04073.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.